CYP11A1 (Cholesterol Side-Chain Cleavage Enzyme, also known as CHASER) is a critical enzyme in steroid biosynthesis and neurosteroid production. This page provides comprehensive information about its structure, function, and role in neurodegenerative diseases including Alzheimer's disease and Parkinson's disease.
| Attribute |
Value |
| Gene Symbol |
CYP11A1 |
| Full Name |
Cytochrome P450 Family 11 Subfamily A Member 1 |
| Alternative Name |
CHASER (Cholesterol Side-chain Cleavage Enzyme) |
| Chromosomal Location |
15q24.2 |
| NCBI Gene ID |
1583 |
| OMIM |
118485 |
| Ensembl ID |
ENSG00000140359 |
| UniProt ID |
P05093 |
| Gene Family |
Cytochrome P450 |
CYP11A1 encodes cytochrome P450scc (side-chain cleavage), the rate-limiting enzyme in all steroid hormone biosynthesis. Located in the inner mitochondrial membrane of steroidogenic cells, CYP11A1 catalyzes the conversion of cholesterol to pregnenolone—the precursor for all steroid hormones including glucocorticoids, mineralocorticoids, androgens, estrogens, and neurosteroids.
In the central nervous system, CYP11A1 is expressed in neurons and glial cells, where it contributes to local neurosteroid synthesis. Neurosteroids such as pregnenolone, allopregnanolone, and dehydroepiandrosterone (DHEA) serve as important neuromodulators affecting GABAergic, glutamatergic, and sigma-1 receptor signaling.
¶ Molecular Structure and Biochemistry
CYP11A1 is a mitochondrial cytochrome P450 enzyme consisting of:
- N-terminal transmembrane domain (residues 1-20): Anchors enzyme to inner mitochondrial membrane
- Heme-binding domain (residues 350-400): Contains conserved cysteine motif for heme coordination
- Substrate-binding pocket: Recognizes cholesterol and mediates its oxidation
The enzyme requires electron transfer from NADPH via adrenodoxin reductase and adrenodoxin for catalytic activity.
CYP11A1 catalyzes a three-step oxidation of cholesterol to pregnenolone:
- 22R-hydroxylation: Adds hydroxyl group at C-22
- 20R,22R-hydroxylation: Adds hydroxyl group at C-20
- C-C bond cleavage: Removes side chain to form pregnenolone
This reaction requires:
- NADPH as electron donor
- Adrenodoxin (electron transfer protein)
- Adrenodoxin reductase
- Molecular oxygen (O₂)
| Property |
Value |
Significance |
| Molecular weight |
~56 kDa |
Mitochondrial enzyme |
| Location |
Inner mitochondrial membrane |
Proximity to cholesterol |
| Electron donors |
Adrenodoxin/Adrenodoxin reductase |
Required for activity |
| Substrate |
Cholesterol |
Rate-limiting step |
| Product |
Pregnenolone |
Precursor for all steroids |
| Km for cholesterol |
~0.5 μM |
Affinity for substrate |
| Turnover rate |
~100/min |
Catalytic efficiency |
CYP11A1 is the first and rate-limiting step in the steroidogenic pathway:
flowchart TD
A["Cholesterol"] --> B["CYP11A1<br>Pregnenolone"]
B --> C["Various Steroid Pathways"]
C --> D["Glucocorticoids<br>Cortisol"]
C --> E["Mineralocorticoids<br>Aldosterone"]
C --> F["Androgens<br>Testosterone"]
C --> G["Estrogens<br>Estradiol"]
C --> H["Neurosteroids<br>Allopregnanolone, DHEA"]
In the brain, CYP11A1 produces neurosteroids that act as:
- GABAergic modulators: Allopregnanolone is a positive allosteric modulator of GABAₐ receptors
- NMDA receptor modulators: Pregnenolone sulfate modulates NMDA receptor activity
- Sigma-1 receptor ligands: Certain neurosteroids bind to sigma-1 receptors
- Neuroprotective agents: Neurosteroids exhibit anti-apoptotic and antioxidant effects
CYP11A1 and its neurosteroid products regulate:
- Synaptic plasticity: Modulation of long-term potentiation and depression
- Stress response: HPA axis regulation via glucocorticoid feedback
- Circadian rhythms: Integration of steroid signaling with circadian clocks
- Energy metabolism: Effects on mitochondrial function
- Inflammatory responses: Anti-inflammatory properties of certain neurosteroids
CYP11A1 is expressed in:
| Tissue |
Expression Level |
Cell Types |
| Adrenal cortex |
Very high |
Zona glomerulosa, fasciculata, reticularis |
| Gonads (ovary/testis) |
High |
Leydig cells, theca cells, granulosa cells |
| Placenta |
High |
Trophoblast cells |
| Brain |
Low-moderate |
Neurons, astrocytes, oligodendrocytes |
| Kidney |
Low |
Adrenal cortical rests |
| Skin |
Low |
Sebaceous glands |
In the central nervous system, CYP11A1 is expressed in:
- Hippocampus: High expression in CA1-CA3 pyramidal neurons
- Cortex: Moderate expression in layers 2-6
- Hypothalamus: High expression in paraventricular and supraoptic nuclei
- Amygdala: Moderate expression in basolateral nucleus
- Cerebellum: Low expression in Purkinje cells
- Substantia nigra: Low-moderate expression in dopaminergic neurons
- Neurons: Primarily in mitochondrial matrix
- Astrocytes: Mitochondrial localization
- Oligodendrocytes: Lower expression, important for myelination
- Microglia: Very low expression
CYP11A1 and neurosteroidogenesis are significantly implicated in AD pathogenesis:
- Brain cholesterol homeostasis is disrupted in AD
- CYP11A1 links cholesterol metabolism to neurosteroid production
- Reduced neurosteroid levels in AD brains correlate with disease severity
- Amyloid-beta accumulation affects steroidogenic cell function
- Allopregnanolone levels are reduced in AD brain and CSF
- Pregnenolone levels decline with age and AD progression
- DHEA/DHEA-S ratios are altered in AD patients
- Allopregnanolone replacement shows promise in preclinical models
- CYP11A1 activators are being investigated
- Neurosteroid-based therapies target multiple AD pathways
CYP11A1 contributes to PD through:
- Dopaminergic neuron survival: Neurosteroids protect substantia nigra neurons
- Mitochondrial function: CYP11A1 is mitochondrial, affects energy metabolism
- Neuroinflammation: Anti-inflammatory effects of neurosteroids
- Levodopa response: Neurosteroids may affect drug metabolism
- Reduced neurosteroid levels in PD patients
- Correlation with disease severity
- Potential as biomarkers
Neurosteroids derived from CYP11A1 show promise in MS:
- Remyelination: Allopregnanolone promotes oligodendrocyte differentiation
- Neuroprotection: Anti-apoptotic effects on neurons
- Immunomodulation: Modulation of T cell responses
- Clinical trials: Allopregnanolone being tested in MS patients
- Reduced neurosteroid levels in ALS patients
- Neurosteroid therapy shows benefit in mouse models
- CYP11A1 expression altered in spinal cord
- Dysregulated neurosteroid metabolism
- GABAergic signaling deficits
- Therapeutic potential of neurosteroid replacement
| Variant |
Location |
Effect |
Clinical Significance |
| Promoter variants |
5' UTR |
Altered expression |
May modify disease risk |
| c.542G>A (p.R181H) |
Exon 3 |
Missense |
Rare, possibly pathogenic |
| c.1013C>T (p.T338I) |
Exon 6 |
Missense |
Function uncertain |
| 3' UTR variants |
Exon 9 |
mRNA stability |
Expression modulation |
- AD risk variants: Certain promoter polymorphisms associated with increased risk
- PD risk variants: May affect neurosteroid levels and neuron survival
- Mood disorders: Variants linked to depression and anxiety
| Neurosteroid |
Target |
Development Stage |
Notes |
| Allopregnanolone |
GABAₐ |
FDA approved (brexagan) |
Postpartum depression |
| Pregnenolone sulfate |
NMDA/Sigma-1 |
Phase II |
AD clinical trial |
| DHEA |
Multiple |
Phase III |
Adjunct therapy |
- Activators: Increase neurosteroid production
- Inhibitors: Used in steroid-sensitive cancers
- Gene therapy: AAV-mediated expression
- BBB penetration: Neurosteroids cross, but some derivatives don't
- Timing: Early intervention may be critical
- Dosing: Chronic vs. acute dosing affects outcomes
- Combination: May need combination with other therapies
- Brexanolone (allopregnanolone) approved for postpartum depression
- Allopregnanolone in AD (NCT03886792)
- Pregnenolone in schizophrenia and depression
CYP11A1 interacts with:
flowchart TD
A["CYP11A1"] --> B["Cholesterol"]
A --> C["Adrenodoxin<br>FDX1"]
A --> D["Adrenodoxin Reductase<br>FDXR"]
A --> E["NADPH"]
B -->|"Converted"| F["Pregnenolone"]
C -.->|Electron transfer| A
D -.->|Electron transfer| C
E -.->|Provides electrons| D
| Partner |
Interaction Type |
Functional Significance |
| Cholesterol |
Substrate |
Steroidogenesis precursor |
| FDX1 (Adrenodoxin) |
Electron transfer |
Catalytic activity |
| FDXR |
Electron transfer |
NADPH oxidation |
| StAR |
Cholesterol import |
Rate of substrate delivery |
| TSPO |
Cholesterol transport |
Mitochondrial import |
CYP11A1 knockout mice:
- Lethal: Complete knockout is embryonic lethal
- Conditional knockouts: Neuron-specific deletion causes deficits
- Heterozygous: Partial reduction shows subtle phenotypes
- CYP11A1 overexpression: Increases neurosteroid levels
- Humanized: Express human CYP11A1 in mouse brain
- Disease models: Combined with AD/PD models
- Altered stress response
- Cognitive deficits
- Seizure susceptibility
- Social behavior changes
- 1950s: Discovery of cholesterol side-chain cleavage activity
- 1960s: Purification of CYP11A1 enzyme
- 1970s: Cloning of CYP11A1 gene
- 1990s: Recognition of neurosteroid synthesis in brain
- 2000s: Link to neurodegenerative diseases
- 2010s: Clinical trials of neurosteroid therapies
- 2020s: FDA approval of brexanolone, ongoing AD trials
- Biomarker development for patient selection
- Combination therapy approaches
- Novel neurosteroid derivatives
- Gene therapy vectors
- Gene expression: Reduced in AD brain
- Enzyme activity: Correlates with neurosteroid levels
- Genetic variants: May predict disease risk
- CSF pregnenolone: Reduced in AD
- CSF allopregnanolone: Reduced in AD/PD
- Plasma DHEA-S: Altered in AD
| Enzyme |
Location |
Function |
| CYP11A1 |
Mitochondria |
Cholesterol → Pregnenolone |
| CYP17A1 |
ER |
17α-hydroxylase/lyase |
| CYP19A1 |
ER |
Aromatase (androgens → estrogens) |
| CYP21A2 |
ER |
21-hydroxylase |
- Differential diagnosis: Distinguishing AD from other dementias
- Disease staging: Correlates with clinical severity
- Treatment monitoring: Response to neurosteroid therapy
Elevated cholesterol/low neurosteroid patients may benefit from:
- Neurosteroid replacement therapy
- CYP11A1 activators
- Cholesterol-lowering adjuncts
- What regulates CYP11A1 expression in different brain cell types?
- How do neurosteroids interact with amyloid and tau pathology?
- What determines regional vulnerability in different diseases?
- Biomarker validation for patient selection
- Optimal dosing and timing strategies
- Combination with disease-modifying therapies
- Novel neurosteroid derivatives with better properties
- Validation of neurosteroid biomarkers
- Development of brain-penetrant analogs
- Gene therapy approaches
- Precision medicine for neurosteroid-based treatments
CYP11A1 (CHASER) represents a critical link between cholesterol metabolism and neurosteroid production in the brain. Its role in producing neurosteroids that modulate GABAergic, glutamatergic, and sigma-1 receptor signaling makes it relevant to multiple neurodegenerative diseases. While neurosteroid replacement therapies show promise, further research is needed to optimize treatment strategies and identify patients most likely to benefit.